Extended Data Fig. 4: CD19/22 CAR T manufacturing flowchart and product breakdown by culture days, manufacturing matrix, dose level, and disease. | Nature Medicine

Extended Data Fig. 4: CD19/22 CAR T manufacturing flowchart and product breakdown by culture days, manufacturing matrix, dose level, and disease.

From: CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Extended Data Fig. 4

a, Manufacturing schematic detailing difference in timing of TransAct washout between the Old and New Matrix. b, Table of Infusion Product Characteristics, categorized by the number of culture days. c, Table of Infusion Product Characteristics, categorized by disease cohort. d, Significant difference in product expansion between the old and new matrix at harvest (p < 0.0001, t-test, two tailed). Box plot center line corresponds to the median; hinges correspond to the 25th and 75th percentiles with the whiskers signifying minimum and maximum values e, No significant difference in vector copy number based on manufacturing matrix. f,g, Significant decreases in CD39+ (p = 0.012, t-test, two-tailed) and PD1+ (p = 0.0003, t-test, two-tailed) CAR T cells manufactured using the new matrix versus the old matrix. h, Significant increases in CD39+ and PD1+ and a significant decrease in CD57+ expression on CD3+ cells from CD4/8 enriched to final CAR T product (p < 0.0001, t-test, two-tailed; for all 3 tests). No difference in LAG3 expression.

Source data

Back to article page